Last reviewed · How we verify
NCT05265130
The Efficacy of YiQiFuMai Injection as an Adjunctive Treatment for Sepsis
Phase 4 trial testing YiQiFuMai in Sepsis in 80 participants. Status unknown.
31 January 2024
Quick facts
| Lead sponsor | Xiyuan Hospital of China Academy of Chinese Medical Sciences |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 28 February 2022 |
| Primary completion | 31 January 2024 |
| Estimated completion | 31 October 2024 |
Drugs / interventions tested
- YiQiFuMai — full drug profile →
- 0.9% Normal Saline 250ml — full drug profile →
Conditions studied
- Sepsis — all drugs for Sepsis →
Sponsor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Who can join
Adults 18 to 90, any sex, with Sepsis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective single center pilot randomized controlled study to assess the efficacy and safety of YiQiFuMai injection (YQFM), a widely used Chinese medicine, as an adjunctive treatment for sepsis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05265130
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sepsis
Currently open trials in the same condition.
- NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
- NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
- NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
- NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
Other Xiyuan Hospital of China Academy of Chinese Medical Sciences trials
Trials by the same sponsor.
- NCT07518420 — Clinical Efficacy Evaluation of Chaizhi Hewei Decoction in the Treatment of Non-Erosive Reflux Disease With Liver-Stomac · NA · not yet recruiting
- NCT06845254 — Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrom · Phase 3 · not yet recruiting
- NCT06618495 — Clinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome · Phase 1, PHASE2 · completed
- NCT06311890 — Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderat · Phase 2 · recruiting
- NCT05638672 — COVID-19 Huashi Baidu Formula Clinical Study · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05265130 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiyuan Hospital of China Academy of Chinese Medical Sciences
- Last refreshed: 3 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05265130.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing